Ireland-based Covidien has introduced its Emprint ablation system with Thermosphere technology, designed to precisely heat and destroy diseased soft tissue (including liver, lung and kidney), and non-resectable liver tumours.
The company said that the new ablation system provides physicians predictable results regardless of target location, tissue type or changes in tissue properties during a procedure.
Covidien president of Early Technologies Chuck Brynelsen said: "Covidien is dedicated to improving patient safety and simplifying procedural options, and this innovative technology enables physicians to deliver precise ablation directly to soft tissue, including liver tumours.
"By providing predictable spherical ablation zones, this technology gives physicians more choices in terms of approach, further simplifying needle placement and saving planning and procedure time."
The Emprint ablation system offers clinicians three kinds of spatial energy control including thermal, field and wavelength, to create predictable and spherical ablation zones.
The company said that its advanced ablation system can be used in three different procedure settings including non-surgical procedures directly through the skin, minimally invasive surgery and open surgery.
In April 2014, the company secured US Food and Drug Administration 510(k) clearance for Emprint Ablation System with Thermosphere Technology.
In addition, the company completed all European requirements to CE Mark the Emprint system and expects to fully launch the product in the US and the European Union (EU) during the current quarter.
The company is focused on developing, manufacturing and selling a diverse range of medical device and supply products for better patient outcomes.
Image: Liver tumour ablation with Emprint Ablation System can be performed without invasive surgery by inserting the system’s antenna into the tumour directly through the skin. Photo: courtesy of Business Wire.
